The newly cleared features include expanded high-definition visualization and contrast between tissues, diffusion weighted imaging for improved distinguishing between normal and tumor tissues and more detailed, brighter and faster anatomical planar imaging, the Cleveland-based company said.
“Today we announce another significant step forward in our drive to better treat cancer patients and further differentiate MRIdian in the marketplace. Our customers are seeking significant improvements on imaging speed, resolution and brightness. They also demand that we avoid artifacts and distortions that have historically and consistently plagued the field. We believe these innovations hit the mark. We will continue to advance the field of MR Guided Radiation Therapy and expand the application of the MRIdian system,” founder & chief scientific officer James Dempsey said in a press release.
Last August, ViewRay said that it closed a $172.5 million offering with funds slated to support working capital and general corporate purposes.
The post ViewRay wins FDA nod for MRIdian system soft tissue visualization capabilities appeared first on MassDevice.